Arctic Bioscience Signs 3-year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis
The agreement signed on Wednesday 3 March relates to the start of a phase IIb study for the treatment of mild to moderate psoriasis with the company's drug candidate, HRO350, developed from herring roe oil.
The agreement signed on Wednesday 3 March relates to the start of a phase IIb study for the treatment of mild to moderate psoriasis with the company's drug candidate, HRO350, developed from herring roe oil.
The purpose of the clinical study is to investigate the efficacy and safety of HRO350 and to establish the optimal dose. The study will include more than 500 patients and is planned to be conducted in seven countries, including Norway. Recruitment of patients will start in Q1 2022.
Arctic Bioscience recently raised NOK 300 million and was listed on Euronext Growth in Oslo on 24 February. The agreement with Smerud Medical Research International ensures that the clinical study on HRO350 is on track and in line with the pharmaceutical development plan.
“We are delighted to have professional support for the implementation of this important study. Smerud Medical Research has a long history and a good reputation as a very professional Contract Research Organization” says Ole Arne Eiksund, CEO of Arctic Bioscience.
Smerud Medical Research International has significant experience with clinical studies in psoriasis and will this week start by identifying centers for the study.
"The development of HRO350 from herring roe oil to a drug is an exceptional story - and it is great to take part in it. We look forward to collaborating with Arctic Bioscience on a comprehensive phase IIb study", says Knut Smerud, CEO of Smerud Medical Research International.
For further information, please contact:
Ole Arne Eiksund
CEO of Arctic Bioscience AS
Mobile: +47 908 43 944
Email: olearne@arctic-bioscience.com
About us
Arctic Bioscience is a biotech company developing and commercializing nutraceutical and pharmaceutical products based on the unique properties of herring roe oil.
The company is developing a novel oral treatment (HRO350) for mild-to-moderate psoriasis, a large global market with significant unmet medical need. Arctic Bioscience will offer convenient treatment in capsule form based on a natural raw material (herring roe). The nutraceutical business has proven traction in the premium Omega 3 market with global expansion potential in B2C and B2B channels. To support its long-term growth strategy, Arctic Bioscience is integrating its value chain and planning a state-of-the-art manufacturing facility with a proprietary production process to enable large-scale high-quality production.
Based in Ørsta on the West Coast of Norway with access to locally sourced herring roe raw material and led by a team with 30+ years of pharma and marine extracts experience, Arctic Bioscience is on a mission to empower healthy lives.